Compare JRI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JRI | IMRX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.7M | 322.8M |
| IPO Year | N/A | 2021 |
| Metric | JRI | IMRX |
|---|---|---|
| Price | $12.57 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 226.9K | ★ 687.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.59 | $1.10 |
| 52 Week High | $14.37 | $10.08 |
| Indicator | JRI | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.56 | 54.60 |
| Support Level | $12.52 | $3.93 |
| Resistance Level | $13.34 | $5.36 |
| Average True Range (ATR) | 0.16 | 0.28 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 1.94 | 84.82 |
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.